159 related articles for article (PubMed ID: 23983021)
1. Anti-tumor necrosis factor α targets protein kinase B/c-Akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis.
Wehrens EJ; Vastert SJ; Mijnheer G; Meerding J; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
Arthritis Rheum; 2013 Dec; 65(12):3279-84. PubMed ID: 23983021
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.
Bulatović Ćalasan M; Vastert SJ; Scholman RC; Verweij F; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
Rheumatology (Oxford); 2015 Sep; 54(9):1724-34. PubMed ID: 25877908
[TBL] [Abstract][Full Text] [Related]
3. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
4. Self-Sustained Resistance to Suppression of CD8+ Teff Cells at the Site of Autoimmune Inflammation Can Be Reversed by Tumor Necrosis Factor and Interferon-γ Blockade.
Petrelli A; Wehrens EJ; Scholman RC; Prakken BJ; Vastert SJ; van Wijk F
Arthritis Rheumatol; 2016 Jan; 68(1):229-36. PubMed ID: 26360332
[TBL] [Abstract][Full Text] [Related]
5. Brief report: etanercept inhibits the tumor necrosis factor α-driven shift of Th17 lymphocytes toward a nonclassic Th1 phenotype in juvenile idiopathic arthritis.
Maggi L; Cimaz R; Capone M; Santarlasci V; Querci V; Simonini G; Nencini F; Liotta F; Romagnani S; Maggi E; Annunziato F; Cosmi L
Arthritis Rheumatol; 2014 May; 66(5):1372-7. PubMed ID: 24470328
[TBL] [Abstract][Full Text] [Related]
6. Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway.
Korotkova M; Westman M; Gheorghe KR; af Klint E; Trollmo C; Ulfgren AK; Klareskog L; Jakobsson PJ
Arthritis Rheum; 2005 Nov; 52(11):3439-47. PubMed ID: 16255020
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
9. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
Tse SM; Laxer RM; Babyn PS; Doria AS
J Rheumatol; 2006 Jun; 33(6):1186-8. PubMed ID: 16755667
[TBL] [Abstract][Full Text] [Related]
10. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
Tse SM; Burgos-Vargas R; Laxer RM
Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
[TBL] [Abstract][Full Text] [Related]
13. Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis.
Crayne CB; Gerhold K; Cron RQ
J Clin Rheumatol; 2013 Apr; 19(3):129-31. PubMed ID: 23519173
[TBL] [Abstract][Full Text] [Related]
14. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis.
Pang L; Wang L; Suo T; Hao H; Fang X; Jia J; Huang F; Tang J
J Rheumatol; 2008 Nov; 35(11):2220-8. PubMed ID: 19004053
[TBL] [Abstract][Full Text] [Related]
16. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
18. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target.
Boettger MK; Hensellek S; Richter F; Gajda M; Stöckigt R; von Banchet GS; Bräuer R; Schaible HG
Arthritis Rheum; 2008 Aug; 58(8):2368-78. PubMed ID: 18668541
[TBL] [Abstract][Full Text] [Related]
20. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
